Medicus Pharma Ltd. Common Stock (MDCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has a cash flow conversion efficiency ratio of -4.559x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.51 Million) by net assets ($1.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Medicus Pharma Ltd. Common Stock to measure how many days the company can operate on defensive assets alone.
Medicus Pharma Ltd. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Medicus Pharma Ltd. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medicus Pharma Ltd. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vereinigte Filzfabriken AG
MU:VFF
|
N/A |
|
SIAV S.P.A.
F:F4U
|
N/A |
|
African Media Entertainment
JSE:AME
|
0.070x |
|
SigmaTron International Inc
NASDAQ:SGMA
|
0.014x |
|
DigiCAP Co. Ltd
KQ:197140
|
-0.074x |
|
Legacy Minerals Holdings Ltd
AU:LGM
|
-0.037x |
|
Union Plastic Public Company Limited
BK:UP
|
-0.006x |
|
OPTIMI HEALTH CORP.
F:8BN
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medicus Pharma Ltd. Common Stock from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see MDCX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.31K | $-22.78 Million | -610.457x | -18574.34% |
| 2024-12-31 | $3.13 Million | $-10.25 Million | -3.269x | +12.63% |
| 2023-12-31 | $1.11 Million | $-4.16 Million | -3.741x | -4417.13% |
| 2022-12-31 | $-12.20 Million | $-1.06 Million | 0.087x | -37.13% |
| 2021-12-31 | $-10.51 Million | $-1.45 Million | 0.138x | -86.91% |
| 2017-12-31 | $-62.65K | $-65.99K | 1.053x | +75.08% |
| 2010-12-31 | $-2.00 Million | $-1.20 Million | 0.602x | -- |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more